Evidence map›Paper›PMID 37151154›Full record

ArticleBrain tumor research and treatment2023

The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1).

Min-Sung Kim, Se-Il Go, Chan Woo Wee, Min Ho Lee, Seok-Gu Kang, Kyeong-O Go, Sae Min Kwon, Woohyun Kim, Yun-Sik Dho, Sung-Hye Park and 14 more

Abstract read
In one paragraph

Article in Brain tumor research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Min-Sung Kim *Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7074-9290
Se-Il Go *Division of Hematology and Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea.ORCID https://orcid.org/0000-0002-3025-6096
Chan Woo Wee *Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0631-7549
Min Ho Lee *Department of Neurosurgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-6174-7579
Seok-Gu KangDepartment of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kyeong-O GoDepartment of Neurosurgery, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
Sae Min KwonDepartment of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Woohyun KimDepartment of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yun-Sik DhoNeuro-Oncology Clinic, National Cancer Center, Goyang, Korea.
Sung-Hye ParkDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Youngbeom SeoDepartment of Neurosurgery, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea.
Sang Woo SongDepartment of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Stephen AhnDepartment of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyuk-Jin OhDepartment of Neurosurgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
Hong In YoonDepartment of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Sea-Won LeeDepartment of Radiation Oncology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Joo Ho LeeDepartment of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Kyung Rae ChoDepartment of Neurosurgery, Konkuk University Medical Center, Seoul, Korea.
Jung Won ChoiDepartment of Neurosurgery, Brain Tumor Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Je Beom HongDepartment of Neurosurgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kihwan HwangDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. nsckpark@snu.ac.kr.ORCID https://orcid.org/0000-0002-2350-9876
Do Hoon LimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. dh8lim@skku.edu.ORCID https://orcid.org/0000-0002-5426-0604
KSNO Guideline Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the coronavirus disease 2019 (COVID-19) pandemic, the need for appropriate treatment guidelines for patients with brain tumors was indispensable due to the lack and limitations of medical resources. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has undertaken efforts to develop a guideline that is tailored to the domestic situation and that can be used in similar crisis situations in the future.

methodsThe KSNO Guideline Working Group was composed of 22 multidisciplinary experts on neuro-oncology in Korea. In order to reach consensus among the experts, the Delphi method was used to build up the final recommendations.

resultsAll participating experts completed the series of surveys, and the results of final survey were used to draft the current consensus recommendations. Priority levels of surgery and radiotherapy during crises were proposed using appropriate time window-based criteria for management outcome. The highest priority for surgery is assigned to patients who are life-threatening or have a risk of significant impact on a patient's prognosis unless immediate intervention is given within 24-48 hours. As for the radiotherapy, patients who are at risk of compromising their overall survival or neurological status within 4-6 weeks are assigned to the highest priority. Curative-intent chemotherapy has the highest priority, followed by neoadjuvant/adjuvant and palliative chemotherapy during a crisis period. Telemedicine should be actively considered as a management tool for brain tumor patients during the mass infection crises such as the COVID-19 pandemic.

conclusionIt is crucial that adequate medical care for patients with brain tumors is maintained and provided, even during times of crisis. This guideline will serve as a valuable resource, assisting in the delivery of treatment to brain tumor patients in the event of any future crisis.

Indexed as

Brain tumorsCrisisDelphiGuidelineKorean Society for Neuro-Oncology

Identifiers

PMID37151154
PMCPMC10172012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.